Search Results - Nancy Wong

  • Showing 1 - 6 results of 6
Refine Results
  1. 1
    Suppressing proteasome mediated processing of topoisomerase II DNA-protein complexes preserves genome integrity

    Suppressing proteasome mediated processing of topoisomerase II DNA-protein complexes preserves genome integrity by Nicholas Sciascia, Wei Wu, Dali Zong, Yilun Sun, Nancy Wong, Sam John, Darawalee Wangsa, Thomas Ried, Samuel F Bunting, Yves Pommier, André Nussenzweig

    Published 2020-02-01
    Get full text
    Article
    Save to List
    Saved in:
  2. 2
    First‐in‐human study with SAR445088: A novel selective classical complement pathway inhibitor

    First‐in‐human study with SAR445088: A novel selective classical complement pathway inhibitor by Timothy Chow, Pirouz Shamszad, Christopher Vinnard, Esther Yoon, Julia Belinski, Irene Karpenko, Laurent Perrin, Kristen Auwarter, Michael Storek, Howard Surks, Nancy Wong, Yehuda Z. Cohen

    Published 2023-04-01
    Get full text
    Article
    Save to List
    Saved in:
  3. 3
    P1471: SUSTAINED EFFICACY OF SUTIMLIMAB, A COMPLEMENT C1S INHIBITOR, IN PATIENTS WITH COLD AGGLUTININ DISEASE: RESULTS FROM PART B OF THE PHASE 3 CADENZA STUDY

    P1471: SUSTAINED EFFICACY OF SUTIMLIMAB, A COMPLEMENT C1S INHIBITOR, IN PATIENTS WITH COLD AGGLUTININ DISEASE: RESULTS FROM PART B OF THE PHASE 3 CADENZA STUDY by Alexander Röth, Sigbjørn Berentsen, Wilma Barcellini, Shirley D’sa, Bernd Jilma, Marc Michel, Ilene C Weitz, Masaki Yamaguchi, Jun-Ichi Nishimura, Josephine Vos, Joan Cid, Michael Storek, Nancy Wong, Ronnie Yoo, Deepthi Jayawardene, Shruti Srivastava, Marek Wardęcki, Frank Shafer, Michelle Lee, Catherine M Broome

    Published 2023-08-01
    Get full text
    Article
    Save to List
    Saved in:
  4. 4
    P1469: INHIBITION OF COMPLEMENT C1S WITH SUTIMLIMAB IN PATIENTS WITH COLD AGGLUTININ DISEASE (CAD): RESULTS FOLLOWING 9-WEEK OFF-TREATMENT PERIOD (WASHOUT) IN THE PHASE 3 CADENZA STUDY

    P1469: INHIBITION OF COMPLEMENT C1S WITH SUTIMLIMAB IN PATIENTS WITH COLD AGGLUTININ DISEASE (CAD): RESULTS FOLLOWING 9-WEEK OFF-TREATMENT PERIOD (WASHOUT) IN THE PHASE 3 CADENZA S... by Alexander Röth, Sigbjørn Berentsen, Wilma Barcellini, Shirley D’sa, Bernd Jilma, Marc Michel, Ilene C Weitz, Masaki Yamaguchi, Jun-Ichi Nishimura, Josephine Vos, Joan Cid, Michael Storek, Nancy Wong, Ronnie Yoo, Deepthi Jayawardene, Katarina Kralova, Marek Wardęcki, Frank Shafer, Michelle Lee, Catherine M Broome

    Published 2023-08-01
    Get full text
    Article
    Save to List
    Saved in:
  5. 5
    Long-term efficacy and safety of continued complement C1s inhibition with sutimlimab in cold agglutinin disease: CADENZA study Part BResearch in context

    Long-term efficacy and safety of continued complement C1s inhibition with sutimlimab in cold agglutinin disease: CADENZA study Part BResearch in context by Alexander Röth, Sigbjørn Berentsen, Wilma Barcellini, Shirley D’Sa, Bernd Jilma, Marc Michel, Ilene C. Weitz, Masaki Yamaguchi, Jun-ichi Nishimura, Josephine M.I. Vos, Joan Cid, Michael Storek, Nancy Wong, Ronnie Yoo, Deepthi Jayawardene, Shruti Srivastava, Marek Wardęcki, Frank Shafer, Michelle Lee, Catherine M. Broome

    Published 2024-08-01
    Get full text
    Article
    Save to List
    Saved in:
  6. 6
    Synthetic viability by BRCA2 and PARP1/ARTD1 deficiencies

    Synthetic viability by BRCA2 and PARP1/ARTD1 deficiencies by Xia Ding, Arnab Ray Chaudhuri, Elsa Callen, Yan Pang, Kajal Biswas, Kimberly D. Klarmann, Betty K. Martin, Sandra Burkett, Linda Cleveland, Stacey Stauffer, Teresa Sullivan, Aashish Dewan, Hanna Marks, Anthony T. Tubbs, Nancy Wong, Eugen Buehler, Keiko Akagi, Scott E. Martin, Jonathan R. Keller, André Nussenzweig, Shyam K. Sharan

    Published 2016-08-01
    Get full text
    Article
    Save to List
    Saved in:

Search Tools: